Cover Image

Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis

ObjectiveThis study focuses on assessing the cost-effectiveness of incorporating toripalimab alongside chemotherapy for the treatment of patients diagnosed with metastatic triple-negative breast cancer from the perspective of the Chinese healthcare system.MethodsA partitioned survival model was cons...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hongfu Cai (Author), Lisheng Huang (Author), Zhiwei Zheng (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
by: Xiaoyan Liu, et al.
Published: (2021)

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
by: Gengwei Huo, et al.
Published: (2023)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2022)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
by: Jiao Xie, et al.
Published: (2023)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
by: Zhiwei Zheng, et al.
Published: (2022)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
by: Zhiwei Zheng, et al.
Published: (2022)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
by: Hongfu Cai, et al.
Published: (2021)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
by: Jingrong Lin, et al.
Published: (2020)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
by: Dey Nandini, et al.
Published: (2021)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
by: Kexun Zhou, et al.
Published: (2023)

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
by: Aurelio Bartolome Castrellon, et al.
Published: (2017)

Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review
by: Anna Martha Hammershøi Madsen, et al.
Published: (2024)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
by: Hao Wang, et al.
Published: (2023)

Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer
by: Meden F. Isaac-Lam
Published: (2024)

Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Palmatine Attenuates Metastatic Lung Colonization of Triple Negative Breast Cancer Cells
by: Selase Ativui, et al.
Published: (2022)

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
by: Yingnan Si, et al.
Published: (2022)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021)

Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer
by: Chao Zheng, et al.
Published: (2022)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017)

TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
by: A. D. Zikiryakhodzhaev, et al.
Published: (2017)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
by: Zhengda Pei, et al.
Published: (2023)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
by: Lee Cheng Phua, et al.
Published: (2020)

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
by: Xueyan Liang, et al.
Published: (2023)

Immunotherapy Treatment for Triple Negative Breast Cancer
by: Elizabeth R. Berger, et al.
Published: (2021)

Immunotherapy for Triple-Negative Breast Cancer
by: Yifeng Cao, et al.
Published: (2021)

Characterization of Triple Negative Breast Cancer
by: Bernardo Enrique Heredia Martínez, et al.
Published: (2020)

Characterization of Triple Negative Breast Cancer
by: Bernardo Enrique Heredia Martínez, et al.
Published: (2020)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer-A Meta-Analysis
by: Zilin Zhang, et al.
Published: (2021)

Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer
by: Maghfira Rahma Azizah, et al.
Published: (2024)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Results of combination treatment for triple-negative breast cancer
by: M. A. Sekundova, et al.
Published: (2014)

Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
by: Xing Wang, et al.
Published: (2024)

The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia
by: Omkar Bhatavdekar, et al.
Published: (2022)

Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
by: Maria Fernanda Imperio Pereira, et al.
Published: (2024)

The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary
by: A. G. Manikhas, et al.
Published: (2016)

Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells
by: Yamila Sanchez, et al.
Published: (2024)